Analytical Solutions, Inc. (ASI) is changing its name to Tergus Pharma, LLC, as part of the company’s new growth strategy in dermatology product development. According to a press statement, Tergus Pharma will provide “a broader range of topical drug development services from concept to commercialization, including product development strategy and design, target product profile development, formulation development, analytical method development and validation, preclinical and clinical supplies manufacturing, program management and logistics, scale-up and technology transfer, regulatory CMC consulting, disease model development, clinical development strategy.”
 
Tergus’ core expertise will remain focused in topical dosage forms, including creams, ointments, lotions, liquids, suspensions, gels, hydrogels, pastes, pump sprays, topical aerosols, foams, microencapsulation, liposomes, suppositories and nail lacquers.
 
Tergus co-founder and chief executive officer, Dr. Vijendra Nalamothu, has 18 years of topical drug product development and commercialization experience. Most recently he served as head of dermatology R&D for Promius Pharma and Dr. Reddy’s Laboratories. Dr. Kailas Thakker, Tergus co-founder and president, has been providing analytical services to the pharmaceutical industry with an emphasis on In Vitro Release Testing (IVRT), functional testing for semisolids and topical products, since 1994.